Partridge Andrew John 4
4 · Turning Point Therapeutics, Inc. · Filed Feb 11, 2022
Insider Transaction Report
Form 4
Partridge Andrew John
EVP & Chief Commercial Officer
Transactions
- Sale
Common Stock
2022-02-09$36.30/sh−221$8,022→ 22,078 total - Award
Common Stock
2022-02-09+16,283→ 38,361 total - Award
Stock Option (right to buy)
2022-02-09+58,600→ 58,600 totalExercise: $37.68Exp: 2032-02-08→ Common Stock (58,600 underlying)
Footnotes (4)
- [F1]Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
- [F2]The Reporting Person acquired 199 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 333 shares on December 10, 2021 pursuant to the ESPP.
- [F3]Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
- [F4]1/48th of the shares vest monthly following February 9, 2022.